Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment

AIDS

Volumn 23, Issue 12, 2009, Pages 1547-1556

  Smith, Kimberly Y ^a   Patel, Parul ^b   Fine, Derek ^c   Bellos, Nicholaos ^d   Sloan, Louis ^e   Lackey, Philip ^f   Kumar, Princy N ^g   Sutherland Phillips, Denise H ^b   Vavro, Cindy ^b   Yau, Linda ^b   Wannamaker, Paul ^b   Shaefer, Mark S ^b  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b GLAXOSMITHKLINE   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Southwest Infectious Disease Associates   (United States)

^e North Texas Infectious Diseases Consultants   (United States)

^f ID Consultants   (United States)

^g GEORGETOWN UNIVERSITY   (United States)

Author keywords

Abacavir; Antiretroviral therapy; Emtricitabine; Lamivudine; Lopinavir; Ritonavir; Tenofovir

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; COTRIMOXAZOLE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LOPINAVIR PLUS RITONAVIR; PLACEBO; VIRUS RNA;

ANEMIA; ARTICLE; ATYPICAL MYCOBACTERIOSIS; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DEEP VEIN THROMBOSIS; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; GLOMERULUS FILTRATION RATE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERLIPIDEMIA; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; KIDNEY FAILURE; LIVER TOXICITY; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MULTICENTER STUDY; NAUSEA; PATIENT ATTITUDE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SIDE EFFECT; TREATMENT RESPONSE; VOMITING;

ADENINE; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CARDIOVASCULAR DISEASES; CD4 LYMPHOCYTE COUNT; DEOXYCYTIDINE; DIDEOXYNUCLEOSIDES; DOUBLE-BLIND METHOD; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MALE; PHOSPHONIC ACIDS; PYRIMIDINONES; RITONAVIR; RNA, VIRAL; TREATMENT OUTCOME;

EID: 68649086238     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32832cbcc2     Document Type: Article

References (29)

1. Crum NF, Riffenburgh RH, Wegner S, Agan BK, Tasker SA, Spooner KM, et al. Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre, early, and late HAART (highly active antiretroviral therapy) eras. J Acquir Immune Defic Syndr 2006; 41:194-200.
2. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d'Arminio Monforte A, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362:22-29.
3. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services; 2008. pp. 1-139. http://www.aidsinfo. nih.gov/ContentFiles/AdultandAdolescentGL.pdf. [Accessed 1 December 2008].
4. Hammer SM, Eron JJ, Reiss P, Schooley RT, Thompson MA, Walmsley S, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300:555-570.
5. Hirsch MS, Gunthard HF, Schapiro JM, Brun-Vezinet F, Clotet B, Hammer SM, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis 2008; 47:266-285.
6. Eron JJ, Yeni P, Gathe J Jr, Estrada V, DeJesus E, Staszewski S, et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised noninferiority trial. Lancet 2006; 386:476-482.
7. Gallant JE, Rodriguez AE, Weinberg WG, Young B, Berger DS, Lim ML, et al. Early virologie nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. J Infect Dis 2005; 192:1921-1930.
8. Markowitz M, Hill-Zabala C, Lang J, DeJesus E, Liao Q, Lanier ER, et al. Induction with abacavir/lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir/lamivudine/zidovudine alone in antiretroviral-naive HIV-1-infected patients. J Acquir Immune Defic Syndr 2005; 39:257-264.
9. Moyle GJ, DeJesus E, Cahn P, Castillo SA, Zhao H, Gordon DN, et al. Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the ziagen once daily in Antiretroviral Combination Study. J Acquir Immune Defic Syndr 2005; 38:417-425.
10. Ortiz R, DeJesus E, Khanlou H, Voronin E, van Lunzen J, Andrade-Villanueva J, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS 2008; 22:1389-1397.
11. Molina JM, Andrade-Villanueva J, Echevarria J, Chetchotisakd P, Corral J, David N, et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 2008; 372: 646-655.
12. Sax P, Tierney C, Collier A, Fischl M, Godfrey C, Jahed N, et al. ACTG 5202: shorter time to virologic failure (VF) with abaca-vir/lamivudine (ABC/3TC) than tenofovir/emtricitabine (TDF/FTC) as part of combination therapy in treatment-naive subjects with screening HIV RNA ≥100,000c/ml [abstract #THAB0303]. 17th International AIDS Conference; Mexico City, Mexico; 2008.
13. Wolf E, Trein A, Schmidt W, Baumgarten A, Jaeger H, Stellbrink HJ. Similar virological response rates for ART-naive subjects starting KVX + LPV/r or TVD + LPV/r: data from the prospective observational STAR cohort [abstract #P7]. 9th International Congress on Drug Therapy in HIV Infection; Glasgow, Scotland; 2008.
14. Eccleston KJ, Bambumba A, Babu CS, Ahmed S, Lee V. Efficacy and safety of tenofovir/emtricitabine compared to abacavir/lamivudine in HIV-1 infected patients in clinical setting: the TEAL study [abstract #P79]. 9th International Congress on Drug Therapy in HIV Infection; Glasgow, Scotland; 2008.
15. Daniels RH, Gazzard BG, Holmes P, Scourfield A, Bower M, Nelson M. Comparing the efficacy of Truvada and Kivexa combination therapy in HAART-naive individuals with different viral loads [abstract #P14]. 9th International Congress on Drug Therapy in HIV Infection; Glasgow, Scotland; 2008.
16. Das S, Arumainayagam J, Kumari B, Chandramani S, Riddell L, Ghanem M. The TOKEN study: safety and efficacy of Truvada or Kivexa in combination with efavirenz in treatment-naive predominantly black African HIV patients [abstract #P15]. 9th International Congress on Drug Therapy in HIV Infection; Glasgow, Scotland; 2008.
17. Young B, Squires K, Patel P, DeJesus E, Bellos N, Berger D. First large, multicenter, open-label study utilizing HLA-BM5701 screening for abacavir hypersensitivity in North America. AIDS 2008; 22:1673-1681.
18. Verhelst D, Monge M, Meynard J, Fouqueray B, Mougenot B, G i rard PM, et al. Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis 2002; 40:1331-1333.
19. Karras A, Lafaurie M, Furco A, Bourgarit A, Droz D, Sereni D, et al. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome and nephrogenic diabetes insipidus. Clin Infect Dis 2003; 36:1070-1073.
20. Zimmerman A, Pizzoferrato T, Bedford J, Morris A, Hoffman R, Braden G. Tenfovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis 2006; 42:283-290.
21. Guest J, Rimland D, Patterson B, Desilva K. Tenofovir-induced nephrotoxicity in the first year of therapy [abstract #778]. 13th Conference on Retroviruses and Opportunistic Infections; Denver, Colorado; 2006.
22. Heffelfinger J, Hanson D, Voetsch A, McNaghten A, Sullivan P. Renal impairment associated with the use of tenofovir [abstract #779]. 13th Conference on Retroviruses and Opportunistic Infections; Denver, Colorado; 2006.
23. Kapitsinou PP, Ansari N. Acute renal failure in an AIDS patient on tenofovir: a case report. J Med Case Reports 2008; 2:94.
24. Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, Dabis F, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study. Lancet 2008; 371:1417-1426.
25. Lundgren JD, Neuhas J, Babiker A, Cooper D, Duprez D, El-Sadr W, et al., for the SMART/INSIGHT and the D:A:D Study groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008; 22:F17-F24.
26. Molina JM, Podsadecki TJ, Johnson MA, Wilkin A, Domingo P, Myers R, et al. A lopinavir/ritonavir-based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 weeks. AIDS Res Hum Retroviruses 2007; 23:1505-1514.
27. Gathe J, da Silva BA, Cohen DE, Loutfy MR, Podzamczer D, Rubio R, et al. A once-daily lopinavir/ritonavir-based regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviral-naive subjects through 48 weeks. J Acquir Immune Defic Syndr 2009; 50:474-481.
28. Epzicom package insert, GlaxoSmithKline, March 2009.
29. DeJesus E, Herrera G, Teofilo E, Gerstoft J, Buendia CB, Brand JD, et al. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin Infect Dis 2004; 39:1038-1046.